Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Schistosomiasis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis - Pipeline Review, H2 2017, provides an overview of the Schistosomiasis (Infectious Disease) pipeline landscape. Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a dark red, blotchy, raised skin rash, pain in the abdomen and joint and muscle pain. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schistosomiasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Schistosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Schistosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively. Schistosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Schistosomiasis (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Schistosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Schistosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Schistosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Schistosomiasis (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Schistosomiasis (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Schistosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Schistosomiasis - Overview Schistosomiasis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Schistosomiasis - Therapeutics Assessment Assessment by Target Assessment by Route of Administration Assessment by Molecule Type Schistosomiasis - Companies Involved in Therapeutics Development Kancera AB Knight Therapeutics Inc LondonPharma Ltd Merck KGaA Salvensis Schistosomiasis - Drug Profiles BDM-I - Drug Profile Product Description Mechanism Of Action R&D Progress EDE-1102 - Drug Profile Product Description Mechanism Of Action R&D Progress intestinal schistosomiasis vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress intestinal schistosomiasis vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress L-Praziquantel - Drug Profile Product Description Mechanism Of Action R&D Progress miltefosine - Drug Profile Product Description Mechanism Of Action R&D Progress R-praziquantel - Drug Profile Product Description Mechanism Of Action R&D Progress schistosomiasis vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Schistosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Schistosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Schistosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Schistosomiasis - Dormant Projects Schistosomiasis - Product Development Milestones Featured News & Press Releases Aug 23, 2013: BioDiem US patent for skin and wound infections Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Schistosomiasis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Schistosomiasis - Pipeline by Kancera AB, H2 2017 Schistosomiasis - Pipeline by Knight Therapeutics Inc, H2 2017 Schistosomiasis - Pipeline by LondonPharma Ltd, H2 2017 Schistosomiasis - Pipeline by Merck KGaA, H2 2017 Schistosomiasis - Pipeline by Salvensis, H2 2017 Schistosomiasis - Dormant Projects, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.